Sarah Cannon has announced the promotion of Dr. Melissa Johnson to program director of lung cancer research.
Since joining Nashville-based Sarah Cannon in 2014, Johnson (pictured) has served as the associate director of lung cancer research at Sarah Cannon Research Institute (the research arm of Sarah Cannon), supporting the growth of early-phase compounds in thoracic malignancies. In her new role, she will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
Johnson will continue to work in early-phase drug development as well as lead the solid tumor immune effector cellular therapy program at Sarah Cannon. She also serves as the chair of the cancer committee at TriStar Centennial Medical Center and served as the scientific committee program chair for the American Society of Clinical Oncology annual meeting earlier this year.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Sarah Cannon Promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research
December 17, 2020 GMT
NASHVILLE, Tenn. (BUSINESS WIRE) Dec 17, 2020
Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
“Since joining Sarah Cannon, Dr. Johnson’s contributions to research have helped transform the treatment options available to patients facing lung cancer,” said David Spigel, MD, Chief Scientific Officer, Sarah Cannon. “As Program Director of Lung Cancer Research, Dr. Johnson will continue to help advance therapies for our patients today and in the future.”